Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-01

Clinical Trial Update: A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial results report long-term safety and tolerability of centanafadine sustained-release tablets in adults with ADHD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Centanafadine sustained-release tablets (centanafadine)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-10-01